Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | EVP & General Manager US | July 16, 2025 | July 17, 2025 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 16, 2025 · Filed July 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,149 |
Reported balance
After 2025-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-07-16 · Sale · Disposed 1,340 · Balance 35,149 F1: This includes an aggregate of 35,136 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This includes an aggregate of 35,136 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 1
1 source rowRow 1 · 2019-11-08 · Disposition to issuer · Disposed 397 · Balance 0 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $10,989 and 178 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.20 · Expires 2029-04-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $13,463 and 220 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $10,989 and 178 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $13,463 and 220 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 08, 2022 Filed Apr 12, 2022 20:10 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 20,516 | $83.01 | $1,703,033.16 |
DisclosureSEC source: 0001209191-22-024136 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,292 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 20,516 | $68.62 | $1,407,807.92 |
DisclosureSEC source: 0001209191-22-024136 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004400 · doc4.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 8,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001641 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,292 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Barry Flannelly's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 56,667 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:12 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066402 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,614 F2 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 19, 2021. The earned shares will vest on the third anniversary of the July 2, 2021 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in February 2021 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded. F3 · balance_after: Including the Performance Stock Units earned on November 19, 2021, this includes an aggregate of 47,989 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:12 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 379 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066402 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,259 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 19, 2021. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 20:14 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 273 | $83.34 | $22,751.82 |
DisclosureSEC source: 0001209191-21-045783 · doc4.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,880 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2021 Restricted Stock Unit Grant, this includes an aggregate of 45,255 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $83.58 | $0.00 |
DisclosureSEC source: 0001209191-21-045783 · doc4.xml · derivative · entry 4 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2031-07-01 F4 · derivative.exercise_date: Beginning July 2, 2021, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:14 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,990 | $83.58 | $166,324.20 |
DisclosureSEC source: 0001209191-21-045783 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,153 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 20:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 7,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045783 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,143 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Barry Flannelly's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 00:18 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.51 | $0.00 |
DisclosureSEC source: 0001209191-21-039691 · doc4.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:52 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 2,744 | $100.00 | $274,400.00 |
DisclosureSEC source: 0001209191-21-005694 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,994 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 44,704 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004365 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F3 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 11,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004365 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,738 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 15, 2021, subject to Barry Flannelly's continued service with the issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 17, 2020 Restricted Stock Unit Grant, this includes an aggregate of 44,704 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:20 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059084 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,216 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 26,521 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:15 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $48.44 | $0.00 |
DisclosureSEC source: 0001209191-20-056888 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2021-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning August 11, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:15 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 20,000 | $86.60 | $1,732,000.00 |
DisclosureSEC source: 0001209191-20-056888 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,984 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 31,950 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:15 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 20,000 | $48.44 | $968,800.00 |
DisclosureSEC source: 0001209191-20-056888 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 20:45 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 8,250 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001209191-20-043742 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 8,250 shares Expires 2030-07-22 F2 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 20:45 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001209191-20-043742 · doc4.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-07-22 F1 · derivative.exercise_date: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:08 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 639 | $104.25 | $66,615.75 |
DisclosureSEC source: 0001209191-20-042791 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,903 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 31,950 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:15 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 404 | $107.79 | $43,547.16 |
DisclosureSEC source: 0001209191-20-041553 · doc4.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,542 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2020 Restricted Stock Unit Grant, this includes an aggregate of 33,339 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:15 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $106.47 | $0.00 |
DisclosureSEC source: 0001209191-20-041553 · doc4.xml · derivative · entry 4 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2030-07-01 F4 · derivative.exercise_date: Beginning July 2, 2020, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:15 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,776 | $106.47 | $189,090.72 |
DisclosureSEC source: 0001209191-20-041553 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,946 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 23:15 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-041553 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,722 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Barry Flannelly's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:09 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 599 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-20-038947 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 599 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:09 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 400 | $110.00 | $44,000.00 |
DisclosureSEC source: 0001209191-20-038947 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,061 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 32,314 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:09 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 599 | $73.21 | $43,852.79 |
DisclosureSEC source: 0001209191-20-038947 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 20:23 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,181 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-20-038461 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,181 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 20:23 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 7,181 | $105.00 | $754,005.00 |
DisclosureSEC source: 0001209191-20-038461 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,862 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 32,314 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 20:23 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 7,181 | $73.21 | $525,721.01 |
DisclosureSEC source: 0001209191-20-038461 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:28 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,583 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-20-025253 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,181 Underlying: Common Stock · 6,583 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:28 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 6,583 | $100.00 | $658,300.00 |
DisclosureSEC source: 0001209191-20-025253 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,342 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 32,314 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:28 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 6,583 | $73.21 | $481,941.43 |
DisclosureSEC source: 0001209191-20-025253 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010045 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,342 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 13, 2020. The performance shares vest 25% annually over four years from the grant date of July 2, 2019, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of revenue-based performance criteria determined by the Issuer's Compensation Committee in February 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 125% of the number of performance shares awarded, and the performance criteria was achieved at the 101.80% level. F2 · balance_after: Including the Performance Stock Units earned on February 13, 2020, this includes an aggregate of 32,314 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:39 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004487 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2030-01-16 F3 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:39 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 11,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004487 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,461 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 17, 2020, subject to Barry Flannelly's continued service with the issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 17, 2020 Restricted Stock Unit Grant, this includes an aggregate of 25,433 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:20 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,582 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-19-058699 · doc4.xml · derivative · entry 6 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,764 Underlying: Common Stock · 6,582 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:20 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 6,582 | $95.00 | $625,290.00 |
DisclosureSEC source: 0001209191-19-058699 · doc4.xml · nonDerivative · entry 4 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,979 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:20 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 6,582 | $73.21 | $481,868.22 |
DisclosureSEC source: 0001209191-19-058699 · doc4.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:20 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 600 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-19-058699 · doc4.xml · derivative · entry 5 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,346 Underlying: Common Stock · 600 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:20 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 600 | $95.00 | $57,000.00 |
DisclosureSEC source: 0001209191-19-058699 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,979 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:20 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 600 | $73.21 | $43,926.00 |
DisclosureSEC source: 0001209191-19-058699 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:31 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,720 | $0.00 Strike: $48.44 | $0.00 |
DisclosureSEC source: 0001209191-19-058122 · doc4.xml · derivative · entry 6 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,720 shares Expires 2021-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning August 11, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:31 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 422 | $0.00 Strike: $48.44 | $0.00 |
DisclosureSEC source: 0001209191-19-058122 · doc4.xml · derivative · entry 5 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 422 shares Expires 2021-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning August 11, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:31 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,720 | $90.00 | $154,800.00 |
DisclosureSEC source: 0001209191-19-058122 · doc4.xml · nonDerivative · entry 4 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,979 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:31 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 1,720 | $48.44 | $83,316.80 |
DisclosureSEC source: 0001209191-19-058122 · doc4.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:31 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 422 | $90.00 | $37,980.00 |
DisclosureSEC source: 0001209191-19-058122 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,979 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:31 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 422 | $48.44 | $20,441.68 |
DisclosureSEC source: 0001209191-19-058122 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 21:45 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $65.20 | $0.00 |
DisclosureSEC source: 0001209191-19-056641 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-04-16 F2 · price: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $13,463 and 220 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. F2 · derivative.exercise_date: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $13,463 and 220 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.